Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy

by Zhe Fu, Alexandra M. Mowday, Jeff B. Smaill, Ian F. Hermans, Adam V. Patterson
Published 2021-04-01

The Flavin Reductase MsuE Is a Novel Nitroreductase that Can Efficiently Activate Two Promising Next-Generation Prodrugs for Gene-Directed Enzyme Prodrug Therapy

by David F. Ackerley, Janine N. Copp, Laura K. Green, Mathew A. Storey, Elsie M. Williams, Jeff B. Smaill, Adam V. Patterson
Published 2013-08-01

Advancing Clostridia to Clinical Trial: Past Lessons and Recent Progress

by Alexandra M. Mowday, Christopher P. Guise, David F. Ackerley, Nigel P. Minton, Philippe Lambin, Ludwig J. Dubois, Jan Theys, Jeff B. Smaill, Adam V. Patterson
Published 2016-06-01

Design, Synthesis and In-Vitro Biological Evaluation of Antofine and Tylophorine Prodrugs as Hypoxia-Targeted Anticancer Agents

by Ziad Omran, Chris P. Guise, Linwei Chen, Cyril Rauch, Ashraf N. Abdalla, Omeima Abdullah, Ikhlas A. Sindi, Peter M. Fischer, Jeff B. Smaill, Adam V. Patterson, Yuxiu Liu, Qingmin Wang
Published 2021-06-01

Subcellular Location of Tirapazamine Reduction Dramatically Affects Aerobic but Not Anoxic Cytotoxicity

by Chris P. Guise, Maria R. Abbattista, Robert F. Anderson, Dan Li, Rana Taghipouran, Angela Tsai, Su Jung Lee, Jeff B. Smaill, William A. Denny, Michael P. Hay, William R. Wilson, Kevin O. Hicks, Adam V. Patterson
Published 2020-10-01